[go: up one dir, main page]

SG11201403683PA - Cell-penetrating peptides - Google Patents

Cell-penetrating peptides

Info

Publication number
SG11201403683PA
SG11201403683PA SG11201403683PA SG11201403683PA SG11201403683PA SG 11201403683P A SG11201403683P A SG 11201403683PA SG 11201403683P A SG11201403683P A SG 11201403683PA SG 11201403683P A SG11201403683P A SG 11201403683PA SG 11201403683P A SG11201403683P A SG 11201403683PA
Authority
SG
Singapore
Prior art keywords
cell
penetrating peptides
peptides
penetrating
Prior art date
Application number
SG11201403683PA
Inventor
Garcia Angelita Rebollo
Fariba Nemati
Didier Decaudin
Sicilia Jeronimo Bravo
Gutierrez Jesus Maria Fominaya
Original Assignee
Univ Pierre Et Marie Curie Paris 6
Inst Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pierre Et Marie Curie Paris 6, Inst Curie filed Critical Univ Pierre Et Marie Curie Paris 6
Publication of SG11201403683PA publication Critical patent/SG11201403683PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747Apoptosis related proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472Cysteine endopeptidases (3.4.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22Cysteine endopeptidases (3.4.22)
    • C12Y304/22062Caspase-9 (3.4.22.62)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
SG11201403683PA 2011-12-27 2012-12-27 Cell-penetrating peptides SG11201403683PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11306784 2011-12-27
PCT/EP2012/076968 WO2013098337A1 (en) 2011-12-27 2012-12-27 Cell-penetrating peptides

Publications (1)

Publication Number Publication Date
SG11201403683PA true SG11201403683PA (en) 2014-10-30

Family

ID=47553033

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201403683PA SG11201403683PA (en) 2011-12-27 2012-12-27 Cell-penetrating peptides
SG10201607271SA SG10201607271SA (en) 2011-12-27 2012-12-27 Cell-penetrating peptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201607271SA SG10201607271SA (en) 2011-12-27 2012-12-27 Cell-penetrating peptides

Country Status (14)

Country Link
US (2) US9353155B2 (en)
EP (1) EP2797616B1 (en)
JP (1) JP6169606B2 (en)
KR (1) KR102071514B1 (en)
CN (1) CN104271147B (en)
AU (1) AU2012360845B2 (en)
BR (1) BR112014016076B1 (en)
CA (1) CA2859712C (en)
DK (1) DK2797616T3 (en)
ES (1) ES2748937T3 (en)
IL (1) IL233280B (en)
PL (1) PL2797616T3 (en)
SG (2) SG11201403683PA (en)
WO (1) WO2013098337A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9364514B2 (en) * 2011-12-27 2016-06-14 Institute Curie Anti-tumor adjuvant therapy
WO2015001045A2 (en) * 2013-07-03 2015-01-08 Universite Pierre Et Marie Curie (Paris 6) Pro-apoptotic ras and raf peptides
EP2868326A1 (en) 2013-11-04 2015-05-06 Université Pierre et Marie Curie (Paris 6) Peptide inhibitors of TEAD/YAP-TAZ interaction
EP2881472A1 (en) * 2013-12-09 2015-06-10 Université Pierre et Marie Curie (Paris 6) A method of predicting a response to an anti-tumor treatment
JP6551825B2 (en) * 2014-02-10 2019-07-31 公立大学法人首都大学東京 Chromatin structure regulator
CN105315348B (en) * 2014-06-23 2018-10-16 天津药物研究院 A kind of transmembrane polypeptide and its preparation method and application
KR101835554B1 (en) 2014-06-24 2018-04-19 서울대학교 산학협력단 Composition comprising C/EBF for promoting differentiation or stability of induced regulatroy T cell and method therefor
EP3277804A1 (en) * 2015-03-31 2018-02-07 Université Pierre et Marie Curie - Paris 6 (UPMC) Pro-apoptotic set and pp2a peptides
CN105418733A (en) * 2015-06-23 2016-03-23 天津药物研究院有限公司 Preparation and application of conjugate of cell penetrating polypeptide and antitumor drug
AU2016348632B2 (en) 2015-11-06 2023-07-13 The Board Of Trustees Of The University Of Illinois Peptides and method for treatment of cardiac arrest
EP3272768A1 (en) * 2016-07-22 2018-01-24 Université Pierre et Marie Curie (Paris 6) Chimeric peptides useful in malaria prophylaxis or treatment
EP3559673B1 (en) 2016-12-22 2022-11-09 Pep-Therapy Cell penetrating peptides with improved internalization properties
EP3582800A4 (en) * 2017-02-19 2020-03-11 The National Institute for Biotechnology in the Negev Ltd. PEPTIDE KINASE INHIBITORS AND METHOD FOR USE THEREOF
US11117930B2 (en) 2017-02-23 2021-09-14 Adrx, Inc. Peptide inhibitors of transcription factor aggregation
CN106831957B (en) * 2017-04-17 2019-12-03 扬州大学 Application of a polypeptide derived from chicken infectious anemia virus VP1-aa 1-19 as a high-efficiency cell-penetrating peptide
CN106995487B (en) * 2017-04-17 2019-12-03 扬州大学 Application of VP1-aa 23-43 polypeptide derived from chicken infectious anemia virus as high-efficiency cell-penetrating peptide
WO2018226992A1 (en) 2017-06-07 2018-12-13 Adrx, Inc. Tau aggregation inhibitors
AU2018318319A1 (en) 2017-08-18 2020-02-20 Adrx, Inc. Tau aggregation peptide inhibitors
CN111729070B (en) * 2020-06-02 2021-03-30 遵义医科大学珠海校区 Application of polypeptide FL15 in preparation of antitumor drugs
WO2023017976A1 (en) * 2021-08-09 2023-02-16 주식회사 쎌트로이 Cationic cell-penetrating peptide and use thereof
CN115028685B (en) * 2022-06-24 2023-10-20 张金强 Cationic bicyclic antibacterial peptide and application thereof
KR20240160718A (en) 2023-05-02 2024-11-12 주식회사 아트프로바이오 Cell penetrating peptides comprising multiple 5-mer alpha-helix fragments and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468223A (en) 1992-11-30 1995-11-21 C.N.R.S. Paris Electrochemotherapy
FR2827866B1 (en) 2001-07-27 2004-12-10 Pasteur Institut SYNTHETIC OR NATURAL PEPTIDES BINDING PROTEIN PHOSPHATASE 2A, IDENTIFICATION METHOD AND USES
WO2004011595A2 (en) 2002-07-26 2004-02-05 Institut Pasteur Vectors for transferring molecules of interest in target cells
US7745574B2 (en) * 2005-05-12 2010-06-29 The Burnham Institute Compounds that regulate apoptosis
US20070184015A1 (en) 2006-02-03 2007-08-09 Soonkap Hahn Novel PEGylation agent
CN101412747B (en) * 2008-10-21 2011-04-20 中国药科大学 Novel cell-penetrating peptide and uses thereof
EP2236603A1 (en) * 2009-03-30 2010-10-06 Universite Pierre Et Marie Curie Pro-apoptotic peptides
US9364514B2 (en) * 2011-12-27 2016-06-14 Institute Curie Anti-tumor adjuvant therapy

Also Published As

Publication number Publication date
CA2859712C (en) 2023-09-19
EP2797616A1 (en) 2014-11-05
AU2012360845B2 (en) 2017-05-11
ES2748937T3 (en) 2020-03-18
US20160257713A1 (en) 2016-09-08
IL233280B (en) 2019-08-29
JP6169606B2 (en) 2017-07-26
DK2797616T3 (en) 2019-10-07
IL233280A0 (en) 2014-08-31
KR102071514B1 (en) 2020-01-30
WO2013098337A1 (en) 2013-07-04
BR112014016076A8 (en) 2017-07-04
US20140364376A1 (en) 2014-12-11
JP2015504050A (en) 2015-02-05
CA2859712A1 (en) 2013-07-04
BR112014016076A2 (en) 2017-06-13
CN104271147B (en) 2018-01-12
BR112014016076B1 (en) 2022-03-15
KR20140128971A (en) 2014-11-06
CN104271147A (en) 2015-01-07
AU2012360845A1 (en) 2014-07-31
US9644001B2 (en) 2017-05-09
EP2797616B1 (en) 2019-07-31
US9353155B2 (en) 2016-05-31
SG10201607271SA (en) 2016-10-28
PL2797616T3 (en) 2020-03-31

Similar Documents

Publication Publication Date Title
IL233280B (en) Cell-penetrating peptides
IL231604B (en) Therapeutic peptides
EP2857033A4 (en) Skin-permeating peptide
SG10201601840RA (en) P53 activating peptides
GB201012651D0 (en) Peptides
GB201111183D0 (en) Peptide
EP2753641A4 (en) Neuroprotective cell-penetrating peptides
ZA201307169B (en) Neuroprotective peptides
GB201115910D0 (en) Peptides
ZA201503127B (en) Peptides
GB201200555D0 (en) Peptide
GB201204868D0 (en) Peptides
GB201223114D0 (en) Novel peptide
EP2891663B8 (en) Psf1-derived peptide
GB201115014D0 (en) Peptides
AU2011903086A0 (en) Peptides
GB201220328D0 (en) Peptides
GB201211740D0 (en) Peptides
GB201207895D0 (en) Peptides
GB201200509D0 (en) Peptides
AU4811P (en) Bidgee Glycine max
GB201112985D0 (en) Polypeptide
GB201106130D0 (en) Polypeptide
GB201112849D0 (en) Polypeptide
GB201105653D0 (en) Anti-microbial peptides